These combined Lov activities might create a hostile inflammatory environment for the tumor, in which antitumor immunity dominates over immune evasion, explaining the reduced tumor multiplicity in Lov-treated Tg-neu mice. The gene discussed is ERBB2; the disease is neoplasm.